Microwave-Assisted Low-Temperature Dehydration Polycondensation of Dicarboxylic Acids and Diols
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Toxicological Basis Data for the Derivation of EU-LCI Values For
TEXTE 223/2020 Toxicological basis data for the derivation of EU- LCI values for neopentyl glycol, diisobutyl succinate, diisobutyl glutarate, 1,2- dimethoxyethane and 1,2-diethoxyethane Final report German Environment Agency TEXTE 223/2020 Ressortforschungsplan of the Federal Ministry for the Enviroment, Nature Conservation and Nuclear Safety Project No. (FKZ) 3719 62 205 0 Report No. FB000359/ENG Toxicological basis data for the derivation of EU-LCI values for neopentyl glycol, diisobutyl succinate, diisobutyl glutarate, 1,2- dimethoxyethane and 1,2-diethoxyethane Final report by Dr. Barbara Werschkun Wissenschaftsbüro, Berlin On behalf of the German Environment Agency Imprint Publisher Umweltbundesamt Wörlitzer Platz 1 06844 Dessau-Roßlau Tel: +49 340-2103-0 Fax: +49 340-2103-2285 [email protected] Internet: www.umweltbundesamt.de /umweltbundesamt.de /umweltbundesamt Report performed by: Wissenschaftsbüro Dr. Barbara Werschkun Monumentenstr. 31a 10829 Berlin Germany Report completed in: May 2020 Edited by: Section II 1.3 Indoor Hygiene, Health-related Environmental Impacts Dr. Ana Maria Scutaru Publication as pdf: http://www.umweltbundesamt.de/publikationen ISSN 1862-4804 Dessau-Roßlau, December 2020 The responsibility for the content of this publication lies with the author(s). TEXTE Toxicological basis data for the derivation of EU-LCI values for neopentyl glycol, diisobutyl succinate, diisobutyl glutarate, 1,2-dimethoxyethane and 1,2-diethoxyethane – Final report Abstract: Toxicological basis data for the derivation of EU-LCI values for neopentyl glycol, diisobutyl succinate, diisobutyl glutarate, 1,2-dimethoxyethane and 1,2-diethoxyethane The objective of this study was the evaluation of toxicological data for five substances as basis for the derivation of EU-LCI values. -
Glutaric Aciduria Lactic Acidosis Glutaryl-Coa Dehydrogenase Deficiency Short-Chain Monocarboxylic Acids
Pediat. Res. 13: 977-981 (1979) C6-C l~-dicarboxylicacid ketosis glutaric aciduria lactic acidosis glutaryl-CoA dehydrogenase deficiency short-chain monocarboxylic acids Ketotic Episodes in Glutaryl-CoA Dehydrogenase Deficiency (Glutaric Aciduria) NIELS GREGERSEN AND NIELS JACOB BRANDT Research Laboratory for Metabolic Disorders, University Department of Clinical Chemistry, Aarhus Kommunehospital, Aarhus, and Section of Clinical Genetics, University Department of Paediatrics, Obstetrics, and Gynaecology, Rigshospitalet, Copenhagen, Denmark Summaw the ketoacidosis, a pronounced lactic acidosis and lactic aciduria is seen in most cases. The present report, together with a recent A 7-yr-old boy with glutaryl-CoA dehydrogenase deficiency (glu- report of Goodman et al. (7), indicates that glutaryl-CoA dehy- taric aciduria), presenting periodic episodes of lethargy and keto- drogenase deficiency (glutaric aciduria) may present ketotic epi- sis, was studied during two such episodes. The urinary excretions sodes, similar to those of the other organic acidurias. of glutaric and 3-OH-glutaric acids were 3100-7900 and 460-660 The patient described by Goodman et al. (7) died in a Reye's &mg creatinine, respectively, during these episodes. Urine sam- syndromelike state. Our patient has had two episodes of ketosis ples collected before and after the attacks contained 100-5300 and and lethargy. During these episodes, the urinary metabolic profiles 230-370 &mg creatinine of glutaric acid and 3-OH-glutaric of organic acids were studied in detail, in an attempt to elucidate acids, respectively. During the episodes, glutaconic acid excretion the pathogenic mechanism leading to the severe clinical and rose from 14-89 to 93-630 pg/mg creatinine. -
Altered Metabolome of Lipids and Amino Acids Species: a Source of Early Signature Biomarkers of T2DM
Journal of Clinical Medicine Review Altered Metabolome of Lipids and Amino Acids Species: A Source of Early Signature Biomarkers of T2DM Ahsan Hameed 1 , Patrycja Mojsak 1, Angelika Buczynska 2 , Hafiz Ansar Rasul Suleria 3 , Adam Kretowski 1,2 and Michal Ciborowski 1,* 1 Clinical Research Center, Medical University of Bialystok, Jana Kili´nskiegoStreet 1, 15-089 Bialystok, Poland; [email protected] (A.H.); [email protected] (P.M.); [email protected] (A.K.) 2 Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-089 Bialystok, Poland; [email protected] 3 School of Agriculture and Food System, The University of Melbourne, Parkville, VIC 3010, Australia; hafi[email protected] * Correspondence: [email protected] Received: 27 June 2020; Accepted: 14 July 2020; Published: 16 July 2020 Abstract: Diabetes mellitus, a disease of modern civilization, is considered the major mainstay of mortalities around the globe. A great number of biochemical changes have been proposed to occur at metabolic levels between perturbed glucose, amino acid, and lipid metabolism to finally diagnoe diabetes mellitus. This window period, which varies from person to person, provides us with a unique opportunity for early detection, delaying, deferral and even prevention of diabetes. The early detection of hyperglycemia and dyslipidemia is based upon the detection and identification of biomarkers originating from perturbed glucose, amino acid, and lipid metabolism. The emerging “OMICS” technologies, such as metabolomics coupled with statistical and bioinformatics tools, proved to be quite useful to study changes in physiological and biochemical processes at the metabolic level prior to an eventual diagnosis of DM. -
Dibasic Acids for Nylon Manufacture
- e Report No. 75 DIBASIC ACIDS FOR NYLON MANUFACTURE by YEN-CHEN YEN October 1971 A private report by the PROCESS ECONOMICS PROGRAM STANFORD RESEARCH INSTITUTE MENLO PARK, CALIFORNIA CONTENTS INTRODUCTION, ....................... 1 SUMMARY .......................... 3 General Aspects ...................... 3 Technical Aspects ..................... 7 INDUSTRY STATUS ...................... 15 Applications and Consumption of Sebacic Acid ........ 15 Applications and Consumption of Azelaic Acid ........ 16 Applications of Dodecanedioic and Suberic Acids ...... 16 Applications of Cyclododecatriene and Cyclooctadiene .... 17 Producers ......................... 17 Prices ........................... 18 DIBASIC ACIDS FOR MANUFACTURE OF POLYAMIDES ........ 21 CYCLOOLIGOMERIZATIONOF BUTADIENE ............. 29 Chemistry ......................... 29 Ziegler Catalyst ..................... 30 Nickel Catalyst ..................... 33 Other Catalysts ..................... 34 Co-Cyclooligomerization ................. 34 Mechanism ........................ 35 By-products and Impurities ................ 37 Review of Processes .................... 38 A Process for Manufacture of Cyclododecatriene ....... 54 Process Description ................... 54 Process Discussion .................... 60 Cost Estimates ...................... 60 A Process for Manufacture of Cyclooctadiene ........ 65 Process Description ................... 65 Process Discussion .................... 70 Cost Estimates ...................... 70 A Process for Manufacture of Cyclodecadiene -
Glutaric Acid Production by Systems Metabolic Engineering of an L-Lysine–Overproducing Corynebacterium Glutamicum
Glutaric acid production by systems metabolic engineering of an L-lysine–overproducing Corynebacterium glutamicum Taehee Hana, Gi Bae Kima, and Sang Yup Leea,b,c,1 aMetabolic and Biomolecular Engineering National Research Laboratory, Systems Metabolic Engineering and Systems Healthcare Cross-Generation Collaborative Laboratory, Department of Chemical and Biomolecular Engineering (BK21 Plus Program), Institute for the BioCentury, Korea Advanced Institute of Science and Technology, Yuseong-gu, 34141 Daejeon, Republic of Korea; bBioInformatics Research Center, Korea Advanced Institute of Science and Technology, Yuseong-gu, 34141 Daejeon, Republic of Korea; and cBioProcess Engineering Research Center, Korea Advanced Institute of Science and Technology, Yuseong-gu, 34141, Daejeon, Republic of Korea Contributed by Sang Yup Lee, October 6, 2020 (sent for review August 18, 2020; reviewed by Tae Seok Moon and Blake A. Simmons) There is increasing industrial demand for five-carbon platform processes rely on nonrenewable and toxic starting materials, chemicals, particularly glutaric acid, a widely used building block however. Thus, various approaches have been taken to biologi- chemical for the synthesis of polyesters and polyamides. Here we cally produce glutaric acid from renewable resources (13–19). report the development of an efficient glutaric acid microbial pro- Naturally, glutaric acid is a metabolite of L-lysine catabolism in ducer by systems metabolic engineering of an L-lysine–overproducing Pseudomonas species, in which L-lysine is converted to glutaric Corynebacterium glutamicum BE strain. Based on our previous study, acid by the 5-aminovaleric acid (AVA) pathway (20, 21). We an optimal synthetic metabolic pathway comprising Pseudomonas previously reported the development of the first glutaric acid- putida L-lysine monooxygenase (davB) and 5-aminovaleramide amido- producing Escherichia coli by introducing this pathway compris- hydrolase (davA) genes and C. -
APPENDIX G Acid Dissociation Constants
harxxxxx_App-G.qxd 3/8/10 1:34 PM Page AP11 APPENDIX G Acid Dissociation Constants § ϭ 0.1 M 0 ؍ (Ionic strength ( † ‡ † Name Structure* pKa Ka pKa ϫ Ϫ5 Acetic acid CH3CO2H 4.756 1.75 10 4.56 (ethanoic acid) N ϩ H3 ϫ Ϫ3 Alanine CHCH3 2.344 (CO2H) 4.53 10 2.33 ϫ Ϫ10 9.868 (NH3) 1.36 10 9.71 CO2H ϩ Ϫ5 Aminobenzene NH3 4.601 2.51 ϫ 10 4.64 (aniline) ϪO SNϩ Ϫ4 4-Aminobenzenesulfonic acid 3 H3 3.232 5.86 ϫ 10 3.01 (sulfanilic acid) ϩ NH3 ϫ Ϫ3 2-Aminobenzoic acid 2.08 (CO2H) 8.3 10 2.01 ϫ Ϫ5 (anthranilic acid) 4.96 (NH3) 1.10 10 4.78 CO2H ϩ 2-Aminoethanethiol HSCH2CH2NH3 —— 8.21 (SH) (2-mercaptoethylamine) —— 10.73 (NH3) ϩ ϫ Ϫ10 2-Aminoethanol HOCH2CH2NH3 9.498 3.18 10 9.52 (ethanolamine) O H ϫ Ϫ5 4.70 (NH3) (20°) 2.0 10 4.74 2-Aminophenol Ϫ 9.97 (OH) (20°) 1.05 ϫ 10 10 9.87 ϩ NH3 ϩ ϫ Ϫ10 Ammonia NH4 9.245 5.69 10 9.26 N ϩ H3 N ϩ H2 ϫ Ϫ2 1.823 (CO2H) 1.50 10 2.03 CHCH CH CH NHC ϫ Ϫ9 Arginine 2 2 2 8.991 (NH3) 1.02 10 9.00 NH —— (NH2) —— (12.1) CO2H 2 O Ϫ 2.24 5.8 ϫ 10 3 2.15 Ϫ Arsenic acid HO As OH 6.96 1.10 ϫ 10 7 6.65 Ϫ (hydrogen arsenate) (11.50) 3.2 ϫ 10 12 (11.18) OH ϫ Ϫ10 Arsenious acid As(OH)3 9.29 5.1 10 9.14 (hydrogen arsenite) N ϩ O H3 Asparagine CHCH2CNH2 —— —— 2.16 (CO2H) —— —— 8.73 (NH3) CO2H *Each acid is written in its protonated form. -
Pharmacokinetics of Sebacic Acid in Rats
European Review for Medical and Pharmacological Sciences 1999; 3: 119-125 Pharmacokinetics of sebacic acid in rats A.M.R. FAVUZZI, G. MINGRONE, A. BERTUZZI*, S. SALINARI**, A. GANDOLFI*, A.V. GRECO Istituto di Medicina Interna e Geriatria, Catholic University - Rome (Italy) *Istituto di Analisi dei Sistemi ed Informatica, CNR - Rome (Italy) **Dipartimento di Informatica e Sistemistica, Facoltà di Ingegneria, “La Sapienza” University - Rome (Italy) Abstract. – The pharmacokinetics of disodi- enteral nutrition (TPN) as an alternate ener- um sebacate (Sb) was studied in Wistar rats of gy source1-3. The advantage of these diacids both sexes. Sebacate was administered either as over conventional lipid substrates (both long intra-peritoneal (i.p.) bolus (six doses ranging from 10 mg to 320 mg) or as oral bolus (two doses: 80 and medium chain triglycerides) is related to and 160 mg). Plasma and urinary concentrations the immediate availability of their com- of Sb and urinary concentrations of Sb and its pounds. The salts of dicarboxylic acids are products of β-oxidation (suberic and adipic acids) highly water soluble and thus can be directly were measured by an improved method using administered through a peripheral venous gas-liquid chromatography/mass-spectrometry. route. Unlike long chain triglycerides (LCT), A single compartment with two linear elimi- or medium chain triglycerides (MCT), which nation routes was selected after no increase in significance was shown by an additional com- are available under emulsion form for clinical partment and after a saturable mechanism was use, they do not require complex and expen- found to be unsuitable. Both renal and non-re- sive production procedures. -
D 2.1 Background Information and Biorefinery Status, Potential and Sustainability
Project no.: 241535 – FP7 Project acronym: Star-COLIBRI Project title: Strategic Targets for 2020 – Collaboration Initiative on Biorefineries Instrument: Specific Support Action Thematic Priority: Coordination and support actions D 2.1 Background information and biorefinery status, potential and Sustainability – Task 2.1.2 Market and Consumers; Carbohydrates – Due date of deliverable: March 31, 2010 Start date of project: 01.11.2009 Duration: 24 months Organisation name of lead contractor for this deliverable: UoY Version: 1.0 Project co-funded by the European Commission within the Seventh Framework Programme (2007-2011) Dissemination level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) Star-COLIBRI - Deliverable 2.1 D 2.1 Background information and biorefinery status, potential and Sustainability – Task 2.1.2 Market and Consumers; Carbohydrates – H.L. Bos, P.F.H. Harmsen & E. Annevelink Wageningen UR – Food & Biobased Research Version 18/03/10 Task 2.1.2 Market and Consumers; Carbohydrates 2 Star-COLIBRI - Deliverable 2.1 Content Management summary ............................................................................................................... 4 1 Introduction ........................................................................................................................ 5 1.1 Task description -
United States Patent Office Patented
2,826,604 United States Patent Office Patented. Mar. 11, 1958 2 (130-140 C.), the decalyl acetate being recoverable from the reaction mixture by distillation of the neutralized re 2,826,604 action liquid. The recovered product was a straw-colored PREPARATION OF DECAHYDRONAPHTHYL fragrant oil, which was established to be 1-decallyl acetate. ACETATE 5 The position of the acetoxy group was determined by William E. Erner, Wilmington, Del, assignor to Houdry hydrolysis of the ester to the alcohol and subsequent Process Corporation, Wilmington, Del, a corporation conversion to decalone-1 by chromic acid-acetic acid oxi of Delaware dation. - The aceto-oxidation of Decalin can be carried out No Drawing. Application June 2, 1955 10 in the presence of oxidation catalysts of the type em Serial No. 512,853 bodied in the metal salts of the lower fatty acids. Cobalt 2 Claims. (C. 260-488) acetate proved outstanding among the metallic-soap oxi dation catalysts studied. The use of benzoyl peroxide at the start of the process has been found advantageous The present invention relates to the preparation of 1 5 in decreasing the induction period and in giving uni decahydronaphthyl alcohols and the corresponding acetic formly high yields. acid ester and ketone derivatives of Said alcohols. The ratios of Decalin - to acetic anhydride in the oper More particularly the invention is concerned with the ation of the process are not critical, but practical con production of saturated polynuclear carbocyclic com siderations favor the use of at least one-half mol of pounds of the type 20 acetic anhydride per mol of Decalin. -
Chemo-Enzymatic Cascades to Produce Cycloalkenes from Bio-Based Resources
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by edoc ARTICLE https://doi.org/10.1038/s41467-019-13071-y OPEN Chemo-enzymatic cascades to produce cycloalkenes from bio-based resources Shuke Wu 1,3*, Yi Zhou 1, Daniel Gerngross 2, Markus Jeschek 2 & Thomas R. Ward 1* Engineered enzyme cascades offer powerful tools to convert renewable resources into value- added products. Man-made catalysts give access to new-to-nature reactivities that may complement the enzyme’s repertoire. Their mutual incompatibility, however, challenges their 1234567890():,; integration into concurrent chemo-enzymatic cascades. Herein we show that compartmen- talization of complex enzyme cascades within E. coli whole cells enables the simultaneous use of a metathesis catalyst, thus allowing the sustainable one-pot production of cycloalkenes from oleic acid. Cycloheptene is produced from oleic acid via a concurrent enzymatic oxi- dative decarboxylation and ring-closing metathesis. Cyclohexene and cyclopentene are produced from oleic acid via either a six- or eight-step enzyme cascade involving hydration, oxidation, hydrolysis and decarboxylation, followed by ring-closing metathesis. Integration of an upstream hydrolase enables the usage of olive oil as the substrate for the production of cycloalkenes. This work highlights the potential of integrating organometallic catalysis with whole-cell enzyme cascades of high complexity to enable sustainable chemistry. 1 Department of Chemistry, University of Basel, Mattenstrasse 24a, BPR 1096, CH-4058 Basel, Switzerland. 2 Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, CH-4058 Basel, Switzerland. 3Present address: Institute of Biochemistry, University of Greifswald, Felix- Hausdorff-Str. -
(12) United States Patent (10) Patent No.: US 6,406,708 B1 Kairnerud Et Al
USOO6406708B1 (12) United States Patent (10) Patent No.: US 6,406,708 B1 Kairnerud et al. (45) Date of Patent: Jun. 18, 2002 (54) THERAPEUTIC COMPOSITIONS WO WO 96/11572 A1 4/1996 WO WO 96/21422 A1 7/1996 (75) Inventors: Lars Kärnerud, Tenhult; Stellan WO WO 98/22083 A1 5/1998 Olmeskog, Aneby, both of (SE) OTHER PUBLICATIONS (73) Assignee: Interhealth AB, Huskvarna (SE) Patent Abstracts of Japan, “JP 61-227517 A, Lion Corp., published Oct. 9, 1986”, vol. 11, No. 69 C-407. (*) Notice: Subject to any disclaimer, the term of this Patent Abstracts of Japan “10-087458 A., Lion Corp., pub patent is extended or adjusted under 35 lished Apr. 7, 1998”. U.S.C. 154(b) by 0 days. Patent Abstracts of Japan, “JP 07-138125A,” Shiseido Co. Ltd., published May 30, 1995, vol. 95, No. 5. (21) Appl. No.: 09/700,215 Hoffmann SL et al., “Safety, Immunogenicity, And Efficacy (22) PCT Filed: May 12, 1999 Of A Malaria Sporozoite Vaccine Administered With Mono phosphoryl Lipid A, Cell Wall Skeleton Of Mycobacteria, (86) PCT No.: PCT/SE99/00819 And Squalane AS Adjuvent” Am J Trop Med Hyg, 51(5), pp. S371 (c)(1), 603–612, Nov. 1994. Abstract. (2), (4) Date: Nov. 13, 2000 Allison AC, “Adjuvants and Immune Enhancement' Int. J. Technol. Assess Health Care, 10(1), pp., 107-120, Winter (87) PCT Pub. No.: WO99/58104 1994. Abstract. Stone HD et al., “Efficacy of Experimental Newcastle Dis PCT Pub. Date: Nov. 18, 1999 ease Water-In-Oil Oil-Emulsion Vaccines Formulated from (30) Foreign Application Priority Data Squalane and Squalane. -
Effect of Oral Sebacic Acid on Postprandial Glycemia, Insulinemia, and Glucose Rate of Appearance in Type 2 Diabetes
Clinical Care/Education/Nutrition/Psychosocial Research ORIGINAL ARTICLE Effect of Oral Sebacic Acid on Postprandial Glycemia, Insulinemia, and Glucose Rate of Appearance in Type 2 Diabetes 1 1 AMERIGO IACONELLI, MD ANGELA FAVUZZI, MD beneficial in terms of reduction of circu- 2 3 AMALIA GASTALDELLI, PHD CHRISTOPHE BINNERT, PHD lating levels of glucose, insulin, and free 1 3 CHIARA CHIELLINI, PHD KATHERINE MACE´, PHD 1 1 fatty acids in type 2 diabetes. Thus, the DONATELLA GNIULI, MD GELTRUDE MINGRONE, MD, PHD availability of snacks poor in fat and that do not induce hyperglycemia and/or overstimulate insulin secretion would be OBJECTIVE — Dicarboxylic acids are natural products with the potential of being an alter- a good tool in the diet of insulin-resistant, nate dietary source of energy. We aimed to evaluate the effect of sebacic acid (a 10-carbon type 2 diabetic subjects. dicarboxylic acid; C10) ingestion on postprandial glycemia and glucose rate of appearance (Ra) in healthy and type 2 diabetic subjects. Furthermore, the effect of C10 on insulin-mediated Dicarboxylic acids are naturally oc- glucose uptake and on GLUT4 expression was assessed in L6 muscle cells in vitro. curring substances produced by both higher plants and animals via -oxidation RESEARCH DESIGN AND METHODS — Subjects ingested a mixed meal (50% car- of fatty acids (6,7). In plants, long-chain bohydrates, 15% proteins, and 35% lipids) containing 0 g (control) or 10 g C10 in addition to dicarboxylic acids are components of nat- the meal or 23 g C10 as a substitute of fats. ural protective polymers, cutin and RESULTS — In type 2 diabetic subjects, the incremental glucose area under the curve (AUC) suberin, which support biopolyesters in- decreased by 42% (P Ͻ 0.05) and 70% (P Ͻ 0.05) in the 10 g C10 and 23 g C10 groups, volved in waterproofing the leaves and respectively.